# Ministry of Defence

Canonical: https://abierto.us/vendors/ministry-of-defence-u6lduqkz2cs8

- UEI: U6LDUQKZ2CS8
- CAGE: KB887
- Location: Salisbury, GBR
- Awards in window: 8 (35 transactions), $9,944,632 obligated, January 10, 2024 to July 21, 2026

## Awarding agencies

- Defense Threat Reduction Agency: 5 awards, $10,032,062
- Office of Assistant Secretary for Preparedness and Response: 1 awards, $0
- National Institutes of Health: 1 awards, $0
- Food and Drug Administration: 1 awards, -$87,430

## Industries

- 541714 Research and Development in Biotechnology (except Nanobiotechnology): $6,125,409
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): $3,942,100
- 325414 Biological Product (except Diagnostic) Manufacturing: $0
- 541712 Professional, Scientific, and Technical Services: -$122,877

## Competition

- Full and Open Competition: 8 awards

## Largest awards

- HDTRA124C0008 (definitive contract): $5,630,591, Defense Threat Reduction Agency. Generation of a Novel Antibody-Antibiotic Conjugate as a Combination Therapy Platform to Treat Melioidosis or Plague.. https://www.usaspending.gov/award/CONT_AWD_HDTRA124C0008_9700_-NONE-_-NONE-/
- HDTRA122C0032 (definitive contract): $3,432,068, Defense Threat Reduction Agency. Non Ionic Surfactant Vesicles (Nisvs) as a Drug Delivery and Targeting System for Antimicrobials.. https://www.usaspending.gov/award/CONT_AWD_HDTRA122C0032_9700_-NONE-_-NONE-/
- HDTRA122C0035 (definitive contract): $510,033, Defense Threat Reduction Agency. Research and Development on Deep Learning Development and Evaluation Framework.. https://www.usaspending.gov/award/CONT_AWD_HDTRA122C0035_9700_-NONE-_-NONE-/
- HDTRA120C0016 (definitive contract): $494,818, Defense Threat Reduction Agency. Pharmacological and Biologic Intervention to Reduce Inflammation and Seizures Caused by Viral Encephalitis. https://www.usaspending.gov/award/CONT_AWD_HDTRA120C0016_9700_-NONE-_-NONE-/
- HHSO10033001T (delivery order): $0, Barda - Aspr / Daappo / Barda DCMA. Close This Task Order. Awarded to the Defence Science and Technology Laboratory (Dstl), UK Is Issued to Characterize a NON-HUMAN Primate Model to Improve Understanding of Inhalation-Acquired Human Melioidosis (Rtor-Bio-0007).. https://www.usaspending.gov/award/CONT_AWD_HHSO10033001T_7505_HHSO100201100012I_7505/
- 75N93024D00010: $0, National Institutes of Health Niaid. Pre-Clinical Models of Infectious Diseases - Task Areas a and B. https://www.usaspending.gov/award/CONT_IDV_75N93024D00010_7529/
- HDTRA117C0028 (definitive contract): -$35,447, Defense Threat Reduction Agency. Crystalcast Toolset. https://www.usaspending.gov/award/CONT_AWD_HDTRA117C0028_9700_-NONE-_-NONE-/
- HHSF223201510066C (definitive contract): -$87,430, FDA Office of Acq Grant SVCS. BAA Contract Titled, "determination of the Efficacy of Antibiotics Against Melioidosis Acquired by Different Routes of Infection.". https://www.usaspending.gov/award/CONT_AWD_HHSF223201510066C_7524_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/ministry-of-defence-u6lduqkz2cs8.